Disease modifying drugs targeting Β-amyloid

American Journal of Alzheimer's Disease and other Dementias

Volumn 27, Issue 5, 2012, Pages 296-300

  Ozudogru, S N ^a   Lippa, C F ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; disease modifying; intervention; pharmacological

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ATORVASTATIN; BAPINEUZUMAB; CELECOXIB; GLUCAGON LIKE PEPTIDE; GRL 8234; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; ISOLIQUIRITIGENIN; METHYLENE BLUE; NAPROXEN; NOOTROPIC AGENT; PLACEBO; SEMAGACESTAT; SIMVASTATIN; TAK 070; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; DISEASE COURSE; DRUG MECHANISM; DRUG SYNTHESIS; EDEMA; ENZYME INHIBITION; HAIR COLOR; HUMAN; MENINGOENCEPHALITIS; METHEMOGLOBINEMIA; NONHUMAN; PATHOGENESIS; PROPHYLAXIS; RASH; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; VASOGENIC EDEMA;

EID: 84864232926     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317512452034     Document Type: Review

References (40)

1. Shen C, Chen Y, Liu H, et al. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. J Biol Chem. 2008 ; 283 (25). 17721-17730
2. Peterson RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characteristics and outcome. Arch Neurol. 1999 ; 56 (3). 303-308 (Pubitemid 29120227)
3. Olazarán J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010 ; 30 (2). 161-178
4. Saura CA. Presenilin/gamma-secretase and inflammation. Front Aging Neurosci. 2010 ; 2: 16
5. Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS, Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 1999 ; 13 (21). 2801-2810
6. Harrison T, Churcher I, Beher D. Gamma-secretase as a target for drug intervention in Alzheimer's disease. Curr Opin Drug Discov Devel. 2004 ; 7 (5). 709-719 (Pubitemid 39329873)
7. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008 ; 65 (8). 1031-1038
8. Samson K.. NerveCenter: Phase III Alzheimer trial halted: search for therapeutic biomarkers continues. Ann Neurol. 2010 ; 68 (4). A9 - A12
9. Imbimbo BP. Giardina GA. ?-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem. 2011 ; 11 (12). 1555-1570
10. Hawkins J, Harrison DC, Ahmed S, et al. Dynamics of AΒ42 reduction in plasma, CSF and brain of rats treated with the ?-secretase modulator, GSM-10h. Neurodegener Dis. 2011 ; 8 (6). 455-464
11. Tang J, Ghosh A. Treating transgenic Alzheimer mice with a Β-secretase inhibitor, what have we learned?. Aging (Albany NY). 2011 ; 3 (1). 14-16
12. Ghosh AK, Gemma S, Tang J. Beta-secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics. 2008 ; 5 (3). 399-408 (Pubitemid 351952491)
13. Chang WP, Huang X, Downs D, et al. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 2010 ; 25 (2). 775-784
14. Luo X, Yan R. Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int J Clin Exp Pathol. 2010 ; 3 (6). 618-628
15. John S, Thangapandian S, Sakkiah S, Lee KW.. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. BMC Bioinformatics. 2011 ; 12 (suppl 1). S28
16. Ma L, Yang Z, Li C, Zhu Z, Shen X, Hu L. Design, synthesis and SAR study of hydroxychalcone inhibitors of human Β-secretase (BACE1). J Enzyme Inhib Med Chem. 2011 ; 26 (5). 643-648
17. Fukumoto H, Takahashi H, Tarui N, et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 ; 30 (33). 11157-11166
18. Evin G, Barakat A, Masters CL. BACE: therapeutic target and potential biomarker for Alzheimer's disease. Int J Biochem Cell Biol. 2010 ; 42 (12). 1923-1926
19. Willem M, Lammich S, Haass C. Function, regulation and therapeutic properties of beta-secretase (BACE1). Semin Cell Dev Biol. 2009 ; 20 (2). 175-182
20. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003 ; 61 (1). 46-54 (Pubitemid 36818745)
21. Lee M, Bard F, Johnson-Wood K, et al. Abeta42 immunization in Alzheimer's disease generates Ab N-terminal antibodies. Ann Neurol. 2005 ; 58 (3). 430-435 (Pubitemid 41266629)
22. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002 ; 8 (11). 1263-1269 (Pubitemid 35373558)
23. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 ; 24 (2). 198-203
24. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 ; 73 (24). 2061-2070
25. Gotz J, Ittner LM, Lim YA. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci. 2009 ; 66 (8). 1321-1325
26. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J Alzheimers Dis. 2005 ; 7 (1). 63-80 (Pubitemid 40387185)
27. Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis. 2010 ; 19 (4). 1205-1219
28. Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003 ; 72 (5). 603-612 (Pubitemid 36578646)
29. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009 ; 80 (1). 13-17
30. Tamboli IY, Barth E, Christian L, et al. Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J Biol Chem. 2010 ; 285 (48). 37405-37414
31. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010 ; 74 (12). 956-964
32. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P.. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2010 ; (8). CD007514
33. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008 ; 70 (19). 1672-1677 (Pubitemid 351644133)
34. McKee AC, Carreras I, Hossain L, et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008 ; 1207: 225-236
35. Wilkinson BL, Cramer PE, Varvel NH, et al. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol Aging. 2012 ; 33 (1). 197.e21 - e32
36. Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008 ; 65 (7). 896-905 (Pubitemid 352008472)
37. Pettersson M, Kauffman GW, am Ende CW, et al. Novel ?-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat. 2011 ; 21 (2). 205-226
38. Scheindlin S. Something old... something blue. Mol Interv. 2008 ; 8 (6). 268-273
39. Peter C, Hongwan D, Küpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000 ; 56 (3). 247-250 (Pubitemid 30456685)
40. Medina DX, Caccamo A, Oddo S. Methylene blue reduces aΒ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011 ; 21 (2). 140-149